scholarly article | Q13442814 |
P50 | author | Daniel S. Perrien | Q56192217 |
Florent Elefteriou | Q83122994 | ||
Jeffry S. Nyman | Q86839283 | ||
P2093 | author name string | Xiangli Yang | |
Eva Harth | |||
Sasidhar Uppuganti | |||
David M Stevens | |||
Guillaume Vignaux | |||
Jean de la Croix Ndong | |||
P2860 | cites work | Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain | Q28506943 |
Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. | Q30531794 | ||
Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1. | Q34020971 | ||
Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia | Q34311779 | ||
Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. | Q35157847 | ||
Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. | Q35225250 | ||
Chondrocytic Atf4 regulates osteoblast differentiation and function via Ihh. | Q35655638 | ||
Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin | Q36838089 | ||
Scoliosis associated with neurofibromatosis | Q36975066 | ||
TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation | Q37307155 | ||
ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae | Q37374302 | ||
Approaches to treating NF1 tibial pseudarthrosis: consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium | Q38088574 | ||
The ras-GTPase activity of neurofibromin restrains ERK-dependent FGFR signaling during endochondral bone formation. | Q38961342 | ||
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors | Q39161270 | ||
Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo | Q39552334 | ||
Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix | Q40699220 | ||
Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice | Q41874233 | ||
Are endogenous BMPs necessary for bone healing during distraction osteogenesis? | Q42011174 | ||
Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate | Q42609566 | ||
Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice | Q42918689 | ||
Controlled branching of polyglycidol and formation of protein-glycidol bioconjugates via a graft-from approach with "PEG-like" arms | Q43446911 | ||
Chemotherapy for hepatoblastoma in children | Q44985270 | ||
Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model. | Q46798931 | ||
Congenital pseudarthrosis of neurofibromatosis type 1: impaired osteoblast differentiation and function and altered NF1 gene expression. | Q50625815 | ||
Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. | Q50722204 | ||
Treatment of a congenital pseudarthrosis of the tibia by osteogenic protein-1 (bone morphogenetic protein-7): a case report. | Q51230929 | ||
Bone morphogenetic protein 7 in the treatment of congenital pseudarthrosis of the tibia. | Q54213661 | ||
Multiple roles for neurofibromin in skeletal development and growth | Q56269967 | ||
BMP4 Is Dispensable for Skeletogenesis and Fracture-Healing in the Limb | Q61758954 | ||
MR imaging of spinal tumors in children with neurofibromatosis 1 | Q78830044 | ||
Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice | Q81042629 | ||
Whole-spine magnetic resonance imaging in patients with neurofibromatosis type 1 and spinal deformity | Q81073484 | ||
Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morphogenetic protein-7 (rhBMP-7). A report of five cases | Q82699821 | ||
P433 | issue | 1 | |
P921 | main subject | osteoblast | Q917177 |
P304 | page(s) | 55-63 | |
P577 | publication date | 2015-01-01 | |
P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
P1476 | title | Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice | |
P478 | volume | 30 |
Q92446396 | An Update on Neurofibromatosis Type 1-Associated Gliomas |
Q38849894 | BMP9-induced osteogenic differentiation is partially inhibited by miR-30a in the mesenchymal stem cell line C3H10T1/2. |
Q42698368 | Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study |
Q47296503 | Controlled JAGGED1 delivery induces human embryonic palate mesenchymal cells to form osteoblasts |
Q101574023 | MEKK2 mediates aberrant ERK activation in neurofibromatosis type I |
Q26800379 | RASopathies: unraveling mechanisms with animal models |
Q43375908 | Regulation of Osteogenic Differentiation of Placental-Derived Mesenchymal Stem Cells by Insulin-Like Growth Factors and Low Oxygen Tension. |
Q55362635 | Somatic activating mutations in MAP2K1 cause melorheostosis. |
Q37522350 | The mechanism of a chitosan-collagen composite film used as biomaterial support for MC3T3-E1 cell differentiation |
Q50069686 | The reduced osteogenic potential of Nf1-deficient osteoprogenitors is EGFR-independent |
Q30357776 | Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis |
Q26747239 | p38 MAPK Signaling in Osteoblast Differentiation |
Search more.